Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma

High‐risk neuroblastoma, a predominantly TP53 wild‐type (wt) tumour, is incurable in >50% patients supporting the use of MDM2 antagonists as novel therapeutics. Idasanutlin (RG7388) shows in vitro synergy with chemotherapies used to treat neuroblastoma. This is the first study to evaluate the in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Cancer
Main Authors: Chen, Lindi, Pastorino, Fabio, Berry, Philip, Bonner, Jennifer, Kirk, Calum, Wood, Katrina M., Thomas, Huw D., Zhao, Yan, Daga, Antonio, Veal, Gareth J., Lunec, John, Newell, David R., Ponzoni, Mirco, Tweddle, Deborah A.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Cancer Therapy and Prevention
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6491995/
https://ncbi.nlm.nih.gov/pubmed/30536898
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.32058
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados